Mark Yarchoan: The “obesity paradox” in cancer immunotherapy
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared a recent article by him and colleagues on X:
“Our first 2025 paper was published today in The Journal for ImmunoTherapy of Cancer (JITC).
Explores the ‘obesity paradox’ in cancer immunotherapy:
- Obese patients have better IO outcomes (despite increased cancer risk).
- Obesity → Increases T-cell exhaustion → Increases ICI benefit.
“Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade“
Authors: Stephanie L Alden, Soren Charmsaz, Howard L Li, Hua-Ling Tsai, Ludmila Danilova, Kabeer Munjal, Madelena Brancati, Aanika Warner, Kathryn Howe, Ervin Griffin, Mari Nakazawa, Chris Thoburn, Jennifer Gizzi, Alexei Hernandez, Nicole E Gross, Erin M Coyne, Elsa Hallab, Sarah S Shin, Jennifer Durham, Evan J Lipson, Yasser Ged, Marina Baretti, Jean Hoffman-Censits, Tanguy Y Seiwert, Aditi Guha, Sanjay Bansal, Laura Tang, G Scott Chandler, Rajat Mohindra, Rachel Garonce-Hediger, Elizabeth M Jaffee, Won Jin Ho, Chester Kao and Mark Yarchoan
More posts featuring Mark Yarchoan.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023